Abstracts tagged "Infection"

Abstract Number: 0798 • ACR Convergence 2022
Uncovering the Relationship Between COVID-19 Outcome Severity and Rheumatic Disease
Natalie Allcott¹, Neha Gupta¹, Namita Raghavan¹, Huzaefah Syed² and Stamatina Danielides³, ¹VCU, Richmond, VA, ²Virginia Commonwealth University Medical Center, Richmond, VA, ³Virginia Commonwealth University Health System, Glen Allen, VA
Background/Purpose: The COVID-19 pandemic has caused great concern amongst immunocompromised patients, especially those with rheumatic diagnoses. While much has been learned in the past two…
Abstract Number: 1449 • ACR Convergence 2022
Incidence and Risk Factors for Active Tuberculosis in Patients with Systemic Lupus Erythematosus: A Multicenter Prospective Cohort Study
Lifan Zhang¹, xiaoqing zou², Lantian Xie³, Jianghao Liu³, zhengrong yang⁴, qifei cao⁴, Chunlei Li⁵, Xiaochuan Sun⁵, Fengchun ZHANG⁶, Yan Zhao⁷, Xiaofeng Zeng⁸ and Xiaoqing Liu¹, ¹Division of Infectious Diseases, Department of Internal medicine, State Key Laboratory of Complex Severe and Rare Disease, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College; Clinical Epidemiology Unit, Peking Union Medical College, International Clinical Epidemiology Network; Center for Tuberculosis Research, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China, ²Division of Infectious Diseases, Department of Internal medicine, State Key Laboratory of Complex Severe and Rare Disease, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College; School of Population Medicine and Public Health, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China, ³Peking Union Medical College Hospital, Peking Union Medical College, Beijing, China, ⁴Division of Infectious Diseases, Department of Internal medicine, State Key Laboratory of Complex Severe and Rare Disease, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China, ⁵Department of Internal medicine, State Key Laboratory of Complex Severe and Rare Disease, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China, ⁶Peking Union Medical College Hospital, Beijing, China, ⁷Department of Rheumatology and Clinical Immunology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Key Laboratory of Rheumatology & Clinical Immunology, Ministry of Education, Beijing, China, ⁸Department of Rheumatology, Peking Union Medical College Hospital (PUMCH), Chinese Academy of Medical Sciences National Clinical Research Center for Dermatologic and Immunologic Diseases (NCRC-DID), Beijing, China
Background/Purpose: The burden of tuberculosis (TB) and systemic lupus erythematosus (SLE) in China are both the second largest in the world. Patients with SLE are…
Abstract Number: 2002 • ACR Convergence 2022
Do SMS and Email Reminders Increase the Rate of Seasonal Influenza Vaccination in RA Patients Treated with Biologics: A Nested Randomized Controlled Trial Within the ART Registry?
Raphaèle Seror¹, Gabriel Baron², Sylvie Miconnet³, Rakiba Belkhir³, Martin Soubrier⁴, pascale thevenot⁵, andre basch⁶, Marie Truchetet⁷, Pascal Claudepierre⁸, Emmanuelle Dernis⁹, Hubert Marotte¹⁰, René-Marc Flipo¹¹, Olivier Brocq¹², Jacques Morel¹³, CARINE SALLIOT¹⁴, Bruno Fautrel¹⁵, Alain Saraux¹⁶, CHARLES LESKE¹⁷, Naïma Hamamouche¹⁸, Thierry schaeverbeke¹⁹, Xavier Mariette²⁰, Adeline Ruyssen-Witrand²¹ and Philippe Ravaud²², ¹University Hospital Paris-Saclay, Le Kremlin Bicêtre, France, ²AP-HP Hôtel Dieu Hospital, Université Paris Descartes, Paris, France, ³Rheumatology departement, Bicêtre, Paris-Saclay university, Le Kremlin Bicêtre, France, ⁴Gabriel-Montpied Hospital, Clermont-Ferrand, France, ⁵French Society of rheumatology, Paris, France, ⁶Infirmerie Protestante de Lyon, Caluire-et-Cuire, France, ⁷Bordeaux University Hospital, Bordeaux, France, ⁸Paris Est Creteil University, Creteil, France, ⁹LE MANS general hospital, LE MANS, France, ¹⁰INSERM 1059, Saint-Etienne, France, ¹¹CHU Lille, Boulogne-Billancourt, France, ¹²Rheumatology- CH Princesse Grace, Monaco, Monaco, ¹³University and CHU Montpellier, Montpellier, France, ¹⁴CHR orleans, Orleans, France, ¹⁵Sorbonne University Paris, France and Pierre Louis Institute of Epidemiology and Public Health, Paris, France, Paris, France, ¹⁶CHU Brest, Brest, France, ¹⁷Hospital, Cholet, France, ¹⁸e-health Services Sanoïa, Gémenos, France, ¹⁹CHU de Bordeaux, Bordeaux, France, ²⁰Paris-Saclay University, Rueil Malmaison, Ile-de-France, France, ²¹CHU de Toulouse, Toulouse, France, ²²Université Paris Cité, Hôtel-Dieu, Paris, France
Background/Purpose: In patients treated with biologics, vaccination against influenza is recommended. However, vaccination coverage remains very low. The use of automatic digital reminders is an…
Abstract Number: 0302 • ACR Convergence 2022
Risk of Infections Between JAK Inhibitors and TNF Inhibitors Among Patients with Rheumatoid Arthritis
SE RIM CHOI¹, Anna Shin², You-Jung Ha², Yun Jong Lee², Eun Bong Lee¹ and Eun Ha Kang², ¹Seoul National University Hospital, Seoul, Republic of Korea, ²Seoul National University Bundang Hospital, Seongnam, Republic of Korea
Background/Purpose: To compare infectious risk between JAK inhibitors (JAKi) versus TNF inhibitors (TNFi) among patients with rheumatoid arthritis (RA) in Korea. Methods: Using 2009-2019 Korea…
Abstract Number: 0800 • ACR Convergence 2022
Antibody Response to Shingrix Vaccination in Patients with Rheumatoid Arthritis, Seronegative Spondyloarthropathy and Systemic Lupus Erythematosus on Immunosuppressive Medications
Alina Kifayat¹, amy Wasserman², Kirk Sperber¹, Deana Nes³, Paul Arnaboldi⁴ and Julia Ash⁵, ¹New York Medical College at Westchester Medical Center, Valhalla, NY, ²New York Medical College at Westchester Medical Center, Armonk, NY, ³Bergen Medical Associates, Ridgewood, NJ, ⁴New York Medical College, Valhalla, NY, ⁵New York Medical College at Westchester Medical Center, Dobbs Ferry, NY
Background/Purpose: In patients with rheumatic diseases herpes zoster (HZ) has been identified as one of the most common infections associated with immunosuppression. Shingrix is a…
Abstract Number: 1453 • ACR Convergence 2022
Prevalence and Associations of Myositis in an Indian Inception Cohort of Lupus
Liza Rajasekhar¹, Vineetha Shobha², Meenakshi Ponnana³, Chengappa Kavadichanda⁴, Ashish J Mathew⁵, Saumya Ranjan Tripathy⁶, Manish Rathi⁷, Parasar Ghosh⁸, Ranjan Gupta⁹, Avinash Jain¹⁰ and Amita Aggarwal¹¹, ¹Nizam's Institute of Medical Sciences, Madhapur, India, ²St. John’s Medical College Hospital, Bangalore, India, ³Nizam's Institute of Medical Sciences, Hyderabad, India, ⁴JIPMER, Pondicherry, Puducherry, India, ⁵Rigshospitalet, Copenhagen, Denmark, ⁶SCB medical college, Cuttack, India, ⁷PGIMER Chandigarh, Chandigarh, India, ⁸Govt of West Bengal, Kolkata, India, Kolkata, West Bengal, India, ⁹All India Institute of Medical Sciences, New Delhi, India, ¹⁰SMS Medical College, Lucknow, India, ¹¹Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, India
Background/Purpose: Muscle inflammation in systemic lupus erythematosus (SLE) usually presents as generalised myalgia in the presence of active disease elsewhere and responds well to treatment.…
Abstract Number: 2052 • ACR Convergence 2022
Vaccine Uptake in Women with Systemic Lupus Erythematosus (SLE) in a Large Urban Teaching Hospital Serving a High-Risk Population
J. Patricia Dhar¹, Forsythe Hannah², Louis Saravolatz³ and Susanna Szpunar⁴, ¹Ascension St. John Hospital and Wayne State University School of Medicine, Bloomfield Hills, MI, ²Michigan Department of Human and Health Services, Lansing, MI, ³Ascension St John Hospital and Medical Center, Wayne State University School of Medicine (affiliate), Grosse Pointe Woods, MI, ⁴Ascension St. John Hospital, Grosse Pointe Woods, MI
Background/Purpose: Infections are a major cause of morbidity & mortality in patients with systemic lupus erythematosus (SLE), including vaccine-preventable infections. SLE patients are considered to…
Abstract Number: 0349 • ACR Convergence 2022
Comparative Risks of Infection with Belimumab versus Oral Immunosuppressants in Patients with Non-Renal Systemic Lupus Erythematosus
Emma Materne¹, Hyon Choi², Baijun Zhou¹, Karen Costenbader³, Yuqing Zhang⁴ and April Jorge¹, ¹Massachusetts General Hospital, Boston, MA, ²MASSACHUSETTS GENERAL HOSPITAL, Lexington, MA, ³Brigham and Women's Hospital, Boston, MA, ⁴Massachusetts General Hospital, Quincy, MA
Background/Purpose: Belimumab, a biologic B-Lymphocyte stimulator (BLyS) inhibitor, was FDA-approved in 2011 for the treatment of active SLE. Initial phase 3 placebo-controlled trials found no…
Abstract Number: 0801 • ACR Convergence 2022
Impact of Diagnosis and Treatment of Tropheryma Whipplei Infection in Patients with Pre-existing Chronic Inflammatory Rheumatic Diseases: Data from the National Tw-IRD Registry
Damien CAILLET PORTILLLO¹, Xavier Puéchal², Yannick Degboe¹, Marie Kostine³, Alexia Michaut⁴, Andre Ramon⁵, Daniel Wendling⁶, Nathalie Costedoat-Chalumeau⁷, Pascal Richette⁸, Hubert Marotte⁹, Justine VIX¹⁰, Jean Jacques Dubost¹¹, Sebastien Ottaviani¹², Gaël Mouterde¹³, Anne Grasland¹⁴, Aline Frazier-Mironer¹⁵, Vincent GERMAIN¹⁶, Fabienne COURY¹⁷, Anne Tournadre¹¹, Martin Soubrier¹⁸, Pauline Brevet¹⁹, Laurent Cavalie²⁰, Laurent Arnaud²¹, Christophe Richez²², Adeline Ruyssen-Witrand²³ and Arnaud Constantin²⁴, ¹Pierre-Paul Riquet University Hospital, Toulouse & Toulouse III University - Paul Sabatier, Rheumatology, Toulouse, France, ²National Referral Center for Rare Systemic Autoimmune Diseases, Cochin Hospital, Paris, France, ³Pellegrin Hospital, University Hospital of Bordeaux, Rheumatology, Bordeaux, France, ⁴Hospital center, Loire Vendée Ocean, Rheumatology, La Roche-sur-Yon, France, La Roche-sur-Yon, France, ⁵University Hospital of DIJON, Rheumatology, Dijon, France, ⁶CHU, University Teaching Hospital, Besançon, France, ⁷Inserm DR Paris 5, Paris, France, ⁸Department of Rheumatology, Hôpital Lariboisière, Assistance Publique-Hôpitaux de Paris, Paris, France, ⁹INSERM 1059, Saint-Etienne, France, ¹⁰University Hospital of poitiers, Rheumatology, Poitiers, France, Poitiers, France, ¹¹University Hospital of Clermont Ferrand, Rheumatology, Clermont-Ferrand, France, ¹²Hopital Bichat-Claude Bernard, Paris, France, ¹³Lapeyronie Hospital, Montpellier, France, ¹⁴Louis-Mourier Hospital, AP-HP, Colombes, Rheumatology, Colombes, France, ¹⁵APHP Hôpital Lariboisire, Paris, France, ¹⁶Pau Hospital, Rheumatology, Pau, France, Pau, France, ¹⁷Pierre-Bénite Hospital, University Hospital Lyon, Rheumatology, Lyon, France, ¹⁸Gabriel-Montpied Hospital, Clermont-Ferrand, France, ¹⁹University Hospital of Rouen, Rheumatology, Rouen, France., Le Havre, France, ²⁰Purpan Hospital, Federal Institute of Biology (IFB), University Hospital, Toulouse, Biology, Toulouse, France, ²¹Hautepierre Hospital, University Hospital of Strasbourg, Rheumatology, Strasbourg, France, ²²Université de Bordeaux, Bordeaux, France, ²³CHU de Toulouse, Toulouse, France, ²⁴Toulouse University Hospital, Toulouse, France
Background/Purpose: Tropheryma whipplei (Tw) infection is a rare condition, characterized by inflammatory joint symptoms in more than 75% of the cases, which can lead the…
Abstract Number: 1469 • ACR Convergence 2022
Risk Factors for Herpes Zoster Among Patients with Systemic Lupus Erythematosus
Caroline Spitznagel, Fedelis Mutiso, Jim Oates and Diane Kamen, Medical University of South Carolina, Charleston, SC
Background/Purpose: Patients with systemic lupus erythematosus (SLE) have a higher prevalence and incidence of herpes zoster (HZ) compared with the general population. Our study was…
Abstract Number: 2059 • ACR Convergence 2022
Association of Hydroxychloroquine with the Incidence of Infectious Disease in Systemic Lupus Erythematosus: Data from the LUNA Registry
Chiharu Hidekawa¹, Ryusuke Yoshimi², Yusuke Saigusa³, Jun Tamura³, Nobuyuki Yajima⁴, Naoki Suzuki⁵, Noriko Kojitani², Yuji Yoshioka⁵, Natsuki Sakurai⁵, Yumiko Sugiyama⁵, Yosuke Kunishita⁶, Daiga Kishimoto⁷, Kana Higashitani⁵, Yuichiro Sato⁵, Takaaki Komiya⁵, Hideto Nagai², Naoki Hamada⁵, Ayaka Maeda⁵, Naomi Tsuchida⁵, Lisa Hirahara², Yutaro Soejima⁵, Kaoru Takase-Minegishi², Yohei Kirino⁵, Ken-ei Sada⁸, Yoshia Miyawaki⁹, Kunihiro Ichinose¹⁰, Shigeru Ohno¹¹, Hiroshi Kajiyama¹², Shuzo Sato¹³, Yasuhiro Shimojima¹⁴, Michio Fujiwara¹⁵ and Hideaki Nakajima⁵, ¹Department of Hematology and Clinical Immunology, Yokohama City University School of Medicine, Yokohama City, Kanagawa Prefecture, Japan, ²Department of Stem Cell and Immune Regulation, Yokohama City University Graduate School of Medicine, Yokohama, Japan, ³Department of Biostatistics, Yokohama City University School of Medicine, Yokohama, Japan, ⁴Division of Rheumatology, Department of Medicine, Showa University School of Medicine, Tokyo, Japan, ⁵Department of Hematology and Clinical Immunology, Yokohama City University School of Medicine, Yokohama, Japan, ⁶Department of Rheumatology, Yokohama Minami Kyosai Hospital, Yokohama, Kanagawa, Japan, ⁷Center for Rheumatic Diseases, Yokohama City University Medical Center, Kanazawa-ku Yokohamashi, Japan, ⁸Department of Clinical Epidemiology, Kochi Medical School, Kochi University, Okayama, Japan, ⁹Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Yokohama, Japan, ¹⁰Department of Immunology and Rheumatology, Division of Advanced Preventive Medical Sciences, Nagasaki University Graduate School of Biomedical Sciences, Yokohama, Japan, ¹¹Center for Rheumatic Disease, Yokohama City University Medical Center, Yokohama, Japan, ¹²Department of Rheumatology and Applied Immunology, Faculty of Medicine, Saitama Medical University, Yokohama, Japan, ¹³Department of Rheumatology, Fukushima Medical University School of Medicine, Hikarigaoka, Japan, ¹⁴Department of Medicine (Neurology and Rheumatology), Shinshu University School of Medicine, Matsumoto, Japan, ¹⁵Department of Rheumatology, Yokohama Rosai Hospital, Yokohama, Japan
Background/Purpose: Infections are significant causes of mortality in patients with systemic lupus erythematosus (SLE), and their prevention is essential. Although some previous reports have shown…
Abstract Number: L16 • ACR Convergence 2021
Breakthrough COVID-19 Infections Post-vaccination Among Immunocompromised Patients with Autoimmune or Inflammatory Rheumatic Diseases: A Retrospective Cohort Analysis from a U.S. Nationally-sampled Electronic Medical Record Data Repository
Jasvinder Singh¹, Namrata Singh², Alfred Anzalone³, Amy Olex⁴, Jing Sun⁵, Vithal Madhira⁶ and Rena Patel⁷, ¹University of Alabama at Birmingham, Birmingham, AL, ²University of Washington, Bellevue, WA, ³University of Nebraska, Omaha, NE, ⁴Virginia Commonwealth University, Richmond, VA, ⁵Johns Hopkins University, Baltimore, MD, ⁶Palila Software, Reno, NV, ⁷Unviersity of Washington, Seattle, WA
Background/Purpose: National U.S. data on breakthrough COVID-19 infection in people with autoimmune or inflammatory rheumatic diseases (AIRD) are limited. Our objective was to assess whether breakthrough COVID-19 infections were increased post-COVID-19-vaccination…
Abstract Number: 0098 • ACR Convergence 2021
Patients with Chronic Inflammatory Rheumatic Diseases Report a Lower Frequency of Infections Than Controls and They Protect Themselves Well Against SARS-CoV-2 Transmission
Iulia Roman, Ioana Andreica, Xenofon Baraliakos, Uta Kiltz and Juergen Braun, Rheumazentrum Ruhrgebiet Herne, Ruhr-Universität Bochum, Herne, Germany
Background/Purpose: The SARS-CoV-2 pandemic has affected life in most countries around the world for more than a year now. It is not entirely clear if…
Abstract Number: 0937 • ACR Convergence 2021
Evaluation of the Safety of Vedolizumab in Combination with Other Immunosuppression Biological Therapy in Patients with Inflammatory Bowel Disease
Gino Chesini¹, Elizabeth Parrott¹, Lauren Fox¹, Jenna Beatty¹, Cassandra Effken¹, Na Yu¹, Florence Hosseini-Aslinia¹ and Megan Krause², ¹University of Kansas Medical Center, Kansas City, KS, ²University of Kansas, Kansas City, KS
Background/Purpose: Inflammatory bowel disease (IBD) causes a wide range of symptomology frequently leading to co-management of disease activity between gastroenterologist and rheumatologists. Recently in efforts…
Abstract Number: 1556 • ACR Convergence 2021
Mortality Rate Related to COVID-19 in Rheumatic and Musculoskeletal Diseases (RMDs)
Ines Perez - Sancristobal¹, Dalifer Freites¹, Leticia Lopez Pedraza², Maria Paula Alvarez Hernandez¹, Jose Ignacio Colomer³, Alfredo Madrid - Garcia², Benjamin Fernandez¹, Cristina Vadillo¹, Luis Rodriguez Rodriguez⁴, Arkaitz Mucientes², Leticia Leon - Mateos² and Lydia Abasolo⁵, ¹Hospital Clínico San Carlos, Reumathology, Madrid, Madrid, Spain, ²Instituto de Investigación Sanitaria del Hospital Clínico San Carlos, Reumathology, Madrid, Spain, ³Fundación para la Investigación Biomedica, Reumathology, Madrid, Spain, ⁴Hospital Clinico San Carlos, Madrid, Spain, ⁵Rheumatology Department, Hospital Clínico San Carlos, Madrid, Spain
Background/Purpose: In patients with rheumatic and musculoskeletal diseases (RMDs) and infected with Covid – 19, a) we want to assess the mortality rate (MR) related…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].